Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.70 and traded as low as $2.40. Akari Therapeutics shares last traded at $2.52, with a volume of 2,425 shares.
Analyst Ratings Changes
Separately, StockNews.com initiated coverage on Akari Therapeutics in a research note on Thursday. They set a “sell” rating on the stock.
Get Our Latest Stock Analysis on Akari Therapeutics
Akari Therapeutics Stock Performance
Akari Therapeutics Company Profile
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
Further Reading
- Five stocks we like better than Akari Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Options Trading – Understanding Strike Price
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What is a buyback in stocks? A comprehensive guide for investors
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
